Combination of MZ1, a potent BRD4 degrader designed using the Proteolysis Targeted Chimeras (PROTACs) technology [13, 14], with the SMO inhibitor MRT-92 yields a synergistic reduction of melanoma cell growth in vitro and in vivo, providing a rationale for a novel therapeutic approach in melanoma. The gene discussed is BRD4; the disease is melanoma.